NCT00779181View on ClinicalTrials.gov

A Dose-Ranging Study of the Safety and Efficacy of ADX415 in the Treatment of Essential Hypertension

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Hypertension
Interventions
DRUG

ADX415

ADX415 taken three times a day to achieve a high total daily dose

DRUG

ADX415

ADX415 taken three times a day to achieve a mid level total daily dose

DRUG

ADX415

ADX415 taken three times a day to achieve a low total daily dose

DRUG

Placebo

Placebo taken three times a day

Trial Locations (3)

78217

San Antonio

78704

Austin

78759

Austin

Sponsors
All Listed Sponsors
lead

Addrenex Pharmaceuticals, Inc.

INDUSTRY

NCT00779181 - A Dose-Ranging Study of the Safety and Efficacy of ADX415 in the Treatment of Essential Hypertension | Biotech Hunter | Biotech Hunter